Sentinel lymph node dissection (SLND) is noninferior to axillary lymph node dissection (ALND) in patients with invasive breast cancer followed up for a median of 6.3 years, but there is concern about late recurrence. In a randomized clinical trial, Giuliano and colleagues studied 891 women who had surgery for breast cancer and found that the noninferiority of SLND for the outcome of overall survival persisted for up to 10 years. In an Editorial, Livingston and Li suggest that less than perfect clinical trials may yield evidence to improve patients’ quality of life without increasing their risk of mortality.
Highlights. JAMA. 2017;318(10):883–885. doi:10.1001/jama.2016.13300